Metabolic & Cardiometabolic
PCOS increases cardiovascular disease
Strong support Metabolic & Cardiometabolic
Part of: • PCOS
RefutedContestedStrong support
consensus score 1.00
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
4 support 0 contradict 0 tested null 0 mixed · 4 sources, 4 independent groups
What the evidence shows
PCOS increases cardiovascular disease and subclinical-atherosclerosis risk.
The evidence (5)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| nhs2-cvd-2023 2023 · J Am Heart Assoc | observational | mixed | moderate | Prospective NHSII cohort: 103,729 women followed 1989-2017 for coronary heart disease (MI, bypass, angioplasty, stent) and stroke. Exposure was self-reported cause of infertility, not a PCOS diagnosis; the authors state 'The diagnosis of ovulatory infertility includes the diagnosis of PCOS'. Among 8,149 women with ovulatory-disorder infertility (161 CHD events vs 966 in gravid women without infertility), CHD 'RR, 1.28 [95% CI, 1.05-1.55]'. No infertility diagnosis reached significance for stroke; stratifying ovulatory infertility by PCOS symptoms showed no meaningful CHD difference. |
| Ollila M-M, Arffman R K, Korhonen E, Morin-Papunen L, Franks S, Junttila J, Piltonen T T 2023 · Eur J Endocrinol | observational | supports | moderate | Prospective Northern Finland Birth Cohort 1966: women classified at age 31 as PCOS by NIH criteria (n = 144) or Rotterdam criteria (n = 386) versus women without any PCOS features. Endpoint: 'major adverse cardiovascular events (MACE), including myocardial infarction (MI), stroke, heart failure and cardiovascular mortality', to age 53. Over the 22-year follow-up the BMI-adjusted HR for MACE was 2.33 (1.26-4.30) for Rotterdam-PCOS and 2.47 (1.18-5.17) for NIH-PCOS; MI alone was more prevalent (P = .010 NIH; P = .019 Rotterdam). The paper does not report control-group size or event counts. |
| Pourahmad B, Majidnia M, Saniee N, Riyahifar S, Moradi Y 2025 · BMC Womens Health | meta-analysis | supports | moderate | Random-effects meta-analysis of observational studies (5 databases, 1990-2025) comparing women with and without PCOS. Pooled clinical cardiovascular disease RR 1.41 (95% CI 1.17-1.71), I2 97.05%; cohort-only subgroup RR 1.57 (1.38-1.79); stroke RR 1.28 (1.10-1.49); hypertension RR 1.45 (1.32-1.61). The CVD pool is given as 26 studies in one place and 28 in another; total participants are not reported. The abstract states 'no significant publication bias was detected' while the limitations state 'Publication bias was not assessed, potentially skewing results.' |
| Sun D, Wu Y, Ding M, Zhu F 2022 · Angiology | meta-analysis | supports | high | Meta-analysis of 96 articles (5550 women with PCOS, 5974 controls) of subclinical-atherosclerosis markers. Versus controls: thicker carotid intima-media thickness (SMD 0.587, 95% CI 0.398-0.776), lower flow-mediated (-0.649, -0.946 to -0.353) and nitroglycerin-mediated vasodilation (-0.502, -0.686 to -0.317), higher pulse wave velocity (0.382, 0.019-0.746), higher coronary artery calcium (OR 2.204, 1.687-2.879). Subgroups by age and BMI stayed significant except PWV by BMI; Begg and Egger tests non-significant. No clinical cardiovascular events measured; per-marker study counts not reported. |
| Wan Z, Zhao J, Ye Y, Sun Z, Li K, Chen Y, Fang Y, Zhang Y, Lin J, Sun P, Zhang T, Shuai P, Li D, Li P, Zheng H, Li X, Liu Y 2024 · Eur J Prev Cardiol | meta-analysis | supports | moderate | Meta-analysis of 17 articles across five databases, plus a Global Burden of Disease 2019 population-attributable-fraction model. 'The risk of CVD was significantly increased in women with PCOS for an all-age group (pooled RR 1.51, 95% confidence interval 1.36-1.69) and 10- to 54-year-olds (1.37, 1.17-1.59).' Modelled PCOS-associated CVD cases rose from 102 530 (1990) to 235 560 (2019), about 0.85% of 2019 CVD new cases. The abstract does not report heterogeneity or publication-bias testing, the per-subgroup article counts, or which CVD endpoints the pooled studies measured. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.